Gilead, Arcus: Positive Interim Update on Phase 3 Lung Cancer Program

 Fourth Interim Analysis Shows Continued Clinically Meaningful Differentiation Across All Efficacy Measures, Including PFS, in Both Domvanalimab-Containing Arms Compared to the Anti-PD-1 Zimberelimab Monotherapy Arm in First-Line NSCLC Patients –

– Data will be Presented on December 20, 2022 at the American Society of Clinical Oncology (ASCO) Monthly Plenary Series –

– Three Phase 3 Domvanalimab Combination Studies in NSCLC are Ongoing –

https://finance.yahoo.com/news/gilead-arcus-biosciences-announce-positive-133000323.html